Viatris Inc
A global healthcare company that makes and sells generic medicines, complex drugs, and iconic brand-name products like Lipitor® and Lyrica®, reaching hundreds of millions of patients across more than a hundred countries. Viatris was created in 2020 when the drugmaker Mylan merged with Upjohn, the off-patent medicines arm of Pfizer, uniting two long pharmaceutical histories. It has since streamlined by selling off its women's health, over-the-counter, and active-ingredient businesses.
Granted 2.06M · Bought 82.0K
Granted 1.97M · Sold 500.0K
Granted 3.00M · Sold 950.0K
Granted 474.5K · Bought 50.4K
Granted 757.9K · Sold 122.7K
Granted 661.7K · Sold 250.0K
Granted 110.6K
Granted 220.0K
Granted 165.2K
Granted 133.2K · Bought 27.7K
Granted 116.1K
Granted 108.6K · Bought 4.4K
Granted 390.4K · Sold 89.4K
Granted 97.5K · Bought 7.7K
Granted 151.6K · Sold 60.8K
Granted 208.1K · Sold 7.0K
Granted 122.5K · Sold 20.0K
Granted 159.7K
Granted 75.2K
Granted 118.0K
Granted 66.3K
Granted 67.7K · Sold 16.0K
Granted 62.7K
Granted 46.5K
Granted 50.5K · Sold 9.4K
Granted 26.0K
Granted 26.0K
Granted 23.3K · Bought 499
Granted 14.5K
Granted 14.3K · Sold 8.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Smith Scott AndrewChief Executive Officer, Director · 28 transactions | — | 1.37M | 2.06M | 82.0K | — |
| Coury Robert JExecutive Chairman, Director · 19 transactions | — | 1.18Mas of Mar 2023 | 1.97M | — | 500.0K |
| Malik RajivDirector · 65 transactions | — | 627.6Kas of Mar 2025 | 3.00M | — | 950.0K |
| Goettler MichaelChief Executive Officer, Director · 25 transactions | — | 323.3Kas of Mar 2023 | 474.5K | 50.4K | — |
| Campbell PaulSee Remarks · 101 transactions | — | 316.5K | 757.9K | — | 122.7K |
| Mauro AnthonySee Remarks · 45 transactions | — | 248.6Kas of Mar 2024 | 661.7K | — | 250.0K |
| Enrietti AndrewSee Remarks · 14 transactions | — | 227.5K | 110.6K | — | — |
| Higgins Melina EDirector · 14 transactions | — | 220.0K | 220.0K | — | — |
| Parrish Mark WDirector · 13 transactions | — | 165.2K | 165.2K | — | — |
| Kilts James MDirector · 13 transactions | — | 161.3K | 133.2K | 27.7K | — |
| Mark Richard ADirector · 13 transactions | — | 115.0K | 116.1K | — | — |
| Korman HarryDirector · 21 transactions | — | 113.2Kas of Mar 2025 | 108.6K | 4.4K | — |
| Roman BrianChief Legal Officer · 59 transactions | — | 112.3Kas of Mar 2025 | 390.4K | — | 89.4K |
| Cornwell W DonDirector · 15 transactions | — | 112.0K | 97.5K | 7.7K | — |
| Ni Xiangyang (Sean)President, Greater China · 28 transactions | — | 111.7Kas of Mar 2024 | 151.6K | — | 60.8K |
| Le Goff CorinneChief Commercial Officer · 21 transactions | — | 108.8K | 208.1K | — | 7.0K |
| Lyons Dillon JoEllenDirector · 14 transactions | — | 102.5K | 122.5K | — | 20.0K |
| Mistras TheodoraChief Financial Officer · 20 transactions | — | 92.8K | 159.7K | — | — |
| Dimick Neil FDirector · 5 transactions | — | 75.2Kas of Mar 2022 | 75.2K | — | — |
| Narula SanjeevChief Financial Officer · 16 transactions | — | 73.9Kas of Mar 2023 | 118.0K | — | — |
| Groothuis Leo FransDirector · 12 transactions | — | 63.4K | 66.3K | — | — |
| Cuneo AndrewSee Remarks · 48 transactions | — | 62.5Kas of Mar 2024 | 67.7K | — | 16.0K |
| Finney Elisha WDirector · 6 transactions | — | 61.5K | 62.7K | — | — |
| Vivaldi Coelho RogerioDirector · 4 transactions | — | 45.4K | 46.5K | — | — |
| van der Meer Mohr PaulineDirector · 13 transactions | — | 39.6Kas of Mar 2023 | 50.5K | — | 9.4K |
| Damelio Frank ADirector · 2 transactions | — | 26.0K | 26.0K | — | — |
| Severino MichaelDirector · 2 transactions | — | 26.0K | 26.0K | — | — |
| Simmons David SDirector · 4 transactions | — | 23.5K | 23.3K | 499 | — |
| Read Ian CDirector · 3 transactions | — | 14.5Kas of Mar 2022 | 14.5K | — | — |
| Taddese MenassieSee Remarks · 11 transactions | — | 0as of May 2022 | 14.3K | — | 8.8K |
| Pfizer Inc10% owner · 2 transactions | — | 0as of Nov 2020 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -1.86M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.